Hoffmann-la Roche Inc.

Unversität Zürich

Eidgenössische Technische Hochschule Zürcih

F. Hoffmann-la Roche Ag

Eidgenossische Technische Hochschule Zurich

Christoph Ullmer

Patrizio Mattei

Caterina Bissantz

Hans G Richter

Rainer Eugen Martin

Daniel Hunziker

Henrietta Dehmlow

Ulrike Obst Sander

Shawn David Erickson

Kyungjin Kim

Sherrie Lynn Pietranico-Cole

Markus Rudolph

Jerome Hert

Petra Schmitz

Marco Prunotto

Matthias Heinrich Nettekoven

Mark Rogers-Evans

Uwe Grether

Stephan Roever

Paul Hebeisen

Harald Mauser

Prabha Saba Karnachi

Zhiwei Wang

Luca Claudio Gobbi

Tanja Schulz-Gasch

Simon Mensah Ametamey

Atsushi Kimbara

Hugues Matile

Patrick Di Giorgio

Bernd Puellmann

Thomas Hartung

Sabine Gruener

Qingping Liu

Sannah Zoffmann Jensen

Juergen Fingerle

Michel Dietz

Sylvie C Meyer Reigner

Wulun Yang

Leo Nicholls

Linjing Mu

Ahmed Haider

Sannah Jensen Zoffmann

The invention provides novel compounds having the general formula (I) wherein R, R, R, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.

Bicyclic compounds as dual ATX/CA inhibitors

The invention provides novel compounds having the general formula (I) wherein R, R, Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.

Compounds having the general formula (I) wherein R, R, Y and W are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.

Diazaspirocycloalkane and azaspirocycloalkane

This invention relates to novel 3-aminopyridines of the formula wherein B, Band Rto Rare as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

3-amino-pyridines as GPBAR1 agonists

The present invention relates to a compound of formula (I) wherein Ris defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.

Radiolabeled cannabinoid receptor 2 ligand

The invention provides novel compounds having the general formula (I) wherein R, R, Y and W are as described herein, compositions including the compounds and methods of using the compounds.

The invention relates to a compound of formula (I)  Wherein R, R, Rand Rare defined as in the description and in the claims. The said compounds of the invention are preferential agoniste of the Carsonabinocid Receptor 2 and thus useful as medicaments and may be used in treatment of chronic pain, atherosclerosis, ischemic/reperfusion injury and other related diseases. A representative compound of this invention is 6-cyclopropylmethoxy-5-(tetrahydro-pyradine-2-carboxglic acid [1-methyl-1-(5-methyl-(1,2,4]oxadiazol-3-yl)-ethyl)-amide.

Pyridine derivatives as agonists of the CB2 receptor

This invention relates to novel 3-aminopyridines of the formula 

This invention relates to novel 1-hydroxyimino-3-phenyl-propanes of the formula wherein Rto Rare as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and may be used as medicaments for the treatment of diseases such as type II diabetes.

1-hydroxyimino-3-phenyl-propanes

This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula wherein A, A, B, Band Rto Rare as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds

The present invention provides an antibody directed to an epitope of a G-protein coupled receptor, wherein the antibody binds to the extracellular N-terminal region of the receptor and the binding of the antibody to the G-protein coupled receptor induces receptor internalization in cells.

Antibodies directed to mGluR7

Substituted pyridines as GPBAR1 agonists

The present invention relates to compounds of the formula wherein Rto Rare as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CBreceptors.

Pyrazine-2-carboxamide derivatives as CB2 receptor modulators

Growing community of inventors

Fischingen, Germany

Christoph Ullmer